Literature DB >> 6313674

Rapid purification and characterization of DNA topoisomerase I from cultured mouse mammary carcinoma FM3A cells.

K Ishii, T Hasegawa, K Fujisawa, T Andoh.   

Abstract

We have previously shown that a DNA topoisomerase I from mouse mammary carcinoma cells is inhibited by heparin. Taking advantage of this enzyme-heparin interaction, we developed a rapid and efficient method of purification of this enzyme to near homogeneity by extraction of chromatin with 0.15 M phosphate buffer followed by two-step column chromatography on heparin-Sepharose and phenyl-Sepharose. Electrophoresis on sodium dodecyl sulfate-polyacrylamide gels revealed that the final preparation is composed of two polypeptides with apparent Mr approximately 98,000 (p98) and 102,000 (p102), p98 comprising 70% and p102 30%. Extraction and renaturation of the polypeptides from the gel shows that both p98 and p102 seem to possess topoisomerase activity. Partial proteolytic digestion of p98 and p102 with Staphylococcus aureus V8 and chymotrypsin yielded a series of identical peptides, indicating that the two polypeptides are structurally related. The enzyme sedimented through sucrose density gradient with s20,w of 4.0 S, and thus is monomeric in solution.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6313674

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.

Authors:  Y Takebayashi; P Pourquier; A Yoshida; G Kohlhagen; Y Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

2.  Cloning and sequencing of Schizosaccharomyces pombe DNA topoisomerase I gene, and effect of gene disruption.

Authors:  T Uemura; K Morino; S Uzawa; K Shiozaki; M Yanagida
Journal:  Nucleic Acids Res       Date:  1987-12-10       Impact factor: 16.971

3.  Optimum DNA relaxation reaction conditions for calf thymus DNA-topoisomerase I are determined by specific enzyme features.

Authors:  S Coderoni; M Paparelli; G L Gianfranceschi
Journal:  Mol Biol Rep       Date:  1990-11       Impact factor: 2.316

4.  Autoantibodies to purified nuclear proteins related to DNA metabolism during ageing and in SLE patients.

Authors:  G C Astaldi Ricotti; M Pazzaglia; A M Martelli; A Cerino; M Bestagno; A Caprelli; S Riva; M A Pedrini; A Facchini
Journal:  Immunology       Date:  1987-07       Impact factor: 7.397

5.  Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I.

Authors:  I I Gromova; E Kjeldsen; J Q Svejstrup; J Alsner; K Christiansen; O Westergaard
Journal:  Nucleic Acids Res       Date:  1993-02-11       Impact factor: 16.971

6.  Mechanism of inhibition of mammalian DNA topoisomerase I by heparin.

Authors:  K Ishii; S Futaki; H Uchiyama; K Nagasawa; T Andoh
Journal:  Biochem J       Date:  1987-01-01       Impact factor: 3.857

7.  Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.

Authors:  T Andoh; K Ishii; Y Suzuki; Y Ikegami; Y Kusunoki; Y Takemoto; K Okada
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

8.  Distamycin inhibition of topoisomerase I-DNA interaction: a mechanistic analysis.

Authors:  U H Mortensen; T Stevnsner; S Krogh; K Olesen; O Westergaard; B J Bonven
Journal:  Nucleic Acids Res       Date:  1990-04-25       Impact factor: 16.971

9.  Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites.

Authors:  H Tamura; C Kohchi; R Yamada; T Ikeda; O Koiwai; E Patterson; J D Keene; K Okada; E Kjeldsen; K Nishikawa
Journal:  Nucleic Acids Res       Date:  1991-01-11       Impact factor: 16.971

10.  The ultimate carcinogen of 4-nitroquinoline 1-oxide does not react with Z-DNA and hyperreacts with B-Z junctions.

Authors:  C Rodolfo; A Lanza; S Tornaletti; G Fronza; A M Pedrini
Journal:  Nucleic Acids Res       Date:  1994-02-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.